# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Benny Leonard (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX008-SYN-TD
- Date: 1946-05-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Miriam Okafor-Rosenthal, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review on the day of the cardiology consultation. **S**

## History of present illness

Mr. Leonard returns two weeks after intake and was seen this morning by Dr. Achebe-Lindqvist of cardiology, who did an echocardiogram, an exercise stress echocardiogram and a coronary calcium scan. The echocardiogram showed thickening of the heart muscle from high blood pressure with a normal pumping function, and the stress test showed no sign of narrowed arteries; his breathlessness at peak exercise came with a very high blood pressure rise. The calcium score was 186. He has taken losartan-hydrochlorothiazide each morning, and his home readings over the past week averaged 146/92 mmHg. He has refereed only short undercards, as advised, and has had no chest tightness on those nights. He is relieved that his license is not at risk and worried about the cost of another medicine. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 146/92 mmHg over seven days |
| Echocardiogram | Concentric hypertrophy, septum 13 mm, mass index 118 g/m2, ejection fraction 62% |
| Stress echocardiogram | About 10.5 METs; no ischemia; peak blood pressure 226/98 mmHg |
| Coronary calcium score | Agatston 186, about the 80th percentile |
| Kidney function | Creatinine 1.04 mg/dL, potassium 4.0 mmol/L two weeks after starting treatment |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest tightness on undercard nights; no palpitations, fainting, orthopnea or ankle swelling |
| Respiratory | Positive | Breathless only at peak effort on the treadmill this morning |
| Constitutional | Negative | No lightheadedness or tiredness on the new tablet |
| Psychiatric | Positive | Worry about money and work, less than at intake |

4 systems reviewed. **S**

## Current medications

- Losartan 50 mg with hydrochlorothiazide 12.5 mg, one tablet each morning **S**
- Atorvastatin 40 mg tablet, one each evening **S**

## Allergies

- No known allergy **S**

## Objective

BP 148/92 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 74.4 kg; BMI 27.3 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4 mmol/L; Urea nitrogen: 16 mg/dL; Creatinine: 1.04 mg/dL; eGFR: 87 mL/min/1.73 m²; Glucose: 94 mg/dL; Left ventricular ejection fraction (echocardiogram): 62%; Interventricular septal thickness in diastole (echocardiogram): 13 mm (high); Left ventricular mass index (echocardiogram): 118 g/m2 (high); Left atrial volume index (echocardiogram): 36 mL/m² (high). All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4 mmol/L at this visit **S**
- Urea nitrogen: 15 mg/dL at baseline, 16 mg/dL at this visit **S**
- Creatinine: 0.98 mg/dL at baseline, 1.04 mg/dL at this visit **S**
- eGFR: 93 mL/min/1.73 m² at baseline, 87 mL/min/1.73 m² at this visit **S**
- Glucose: 96 mg/dL at baseline, 94 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 148/92 mmHg, pulse 74 |
| Cardiovascular | Regular rhythm; sustained apex beat; fourth heart sound; no murmur at rest or with Valsalva; no edema |
| Respiratory | Clear |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertensive heart disease** (I11.9). Dr. Achebe-Lindqvist finds concentric left ventricular hypertrophy from hypertension, not hypertrophic cardiomyopathy or an athlete's heart, with normal systolic function and grade 1 diastolic dysfunction. The exertional breathlessness and chest tightness came from a steep rise in blood pressure on effort in a stiff, thickened ventricle, not from ischemia. Home blood pressure is still above target. **S**
   - Continue losartan 50 mg with hydrochlorothiazide 12.5 mg; send home readings weekly; dose review in five weeks.
   - Short undercards until home readings are below 140/90 mmHg, then full cards.
   - Water between bouts; stop and hand over a bout for chest discomfort, faintness or palpitations.
   - Hold the tablet on sick days and call.
2. **Coronary atherosclerosis (calcium score 186)** (I25.10). A calcium score of 186 puts him above the threshold where a statin is clearly indicated; LDL 160 mg/dL. Aspirin was discussed with him by the cardiologist and is not started while his blood pressure is uncontrolled. **S**
   - Atorvastatin 40 mg each evening from today; a generic at low cost.
   - Lipid panel at eight to twelve weeks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Clinic blood pressure, average of two seated readings | Every visit | Completed today | 148/92 mmHg |
| Self-management | Home blood pressure monitoring (validated upper-arm cuff), readings sent weekly | Every day during titration; then a week before each visit | Completed today | Seven-day average 146/92 mmHg; above the target of 130/80 |
| Laboratory | Basic metabolic panel (sodium, potassium, creatinine, eGFR) | Two to four weeks after starting or changing an ARB or diuretic; then every six months | Completed today | Two weeks after starting losartan-hydrochlorothiazide: sodium 139, potassium 4.0 mmol/L, creatinine 1.04 mg/dL, eGFR 87 |
| Laboratory | Urine albumin-to-creatinine ratio | At diagnosis, then yearly | Up to date | 22 mg/g at intake, normal |
| Laboratory | HbA1c | At diagnosis, then yearly | Up to date | 5.5% at intake |
| Laboratory | ALT before a statin | Once before starting a statin | Up to date | 24 U/L at intake |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Up to date | LDL 160 mg/dL at intake; recheck eight to twelve weeks after today's start |
| Imaging | 12-lead ECG | At diagnosis; then as clinically indicated | Up to date | Intake ECG: left ventricular hypertrophy by voltage, QTc 418 ms |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or suspected hypertrophy; repeat in six to twelve months to judge regression | Completed today | Ejection fraction 62%, septum 13 mm, mass index 118 g/m2, left atrial volume index 36 mL/m2; no outflow obstruction |
| Imaging | Stress testing or coronary imaging | For new or changed exertional symptoms; not for routine surveillance | Completed today | Exercise stress echocardiogram for exertional symptoms: no inducible ischemia; coronary calcium score 186 |
| Examination | Symptoms: exertional chest discomfort, breathlessness, palpitations, fainting | Every visit | Completed today | No chest tightness on undercard nights |
| Examination | Weight, BMI and physical activity | Every visit | Completed today | 74.4 kg, BMI 27.3; walking more |
| Medication safety | Adherence and side effects (cough, edema, muscle aches, lightheadedness) | Every visit | Completed today | Takes the tablet each morning; no lightheadedness or cough |
| Self-management | Return to work: refereeing, heat and hydration, warning symptoms, defibrillator at the venue | Before return to full exertion; then every visit | Completed today | Undercards only until home blood pressure is below 140/90; plan given in writing |
| Self-management | Sick-day rules | When starting an ARB or diuretic | Completed today | Hold the tablet on a day of vomiting, diarrhea or inability to drink, and call |
| Medication safety | Aspirin decision | When risk changes | Deferred | Not started while blood pressure is uncontrolled; to be revisited once it is controlled |
| Referral | Cardiology consultation | At intake | Completed today | Seen by Dr. Achebe-Lindqvist today |

## Goal progress

- Find the cause of the exertional breathlessness and chest tightness. Outcome by 1946-05-26: No inducible ischemia; symptoms from hypertensive heart disease with an exaggerated blood pressure response. **S**
- Blood pressure below 130/80 mmHg at home and in the clinic. In progress; target 1946-08-25. **S**
- LDL below 70 mg/dL and at least 50% lower than at intake. In progress; target 1946-07-28. **S**
- Keep refereeing full cards safely, without symptoms. In progress; target 1947-05-12. **S**
- Regression of left ventricular hypertrophy on a repeat echocardiogram. In progress; target 1947-05-26. **S**

## Medication changes

- Started: Atorvastatin 40 mg tablet, one each evening **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain (2021), American Heart Association and American College of Cardiology (Circulation 2021;144(22):e368-e454)
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (2026), American College of Cardiology and American Heart Association (Circulation 2026;153(17):e1154-e1276)
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease (2019), American College of Cardiology and American Heart Association (Circulation 2019;140(11):e596-e646)
- Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (2015), American Heart Association and American College of Cardiology (Circulation 2015;132(22):e298-e302)
- CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and ischemic heart disease monographs (2026), Aether Forge

## Follow-up

- Home readings weekly by phone. Seven-week review at the end of June with a basic metabolic panel; lipid panel at eight to twelve weeks. **S**
- Next scheduled visit 1946-06-30: seven-week review: home blood pressure, the first weeks back at full cards, symptoms, and a dose increase. **S**
